EA201000077A1 - Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей - Google Patents

Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей

Info

Publication number
EA201000077A1
EA201000077A1 EA201000077A EA201000077A EA201000077A1 EA 201000077 A1 EA201000077 A1 EA 201000077A1 EA 201000077 A EA201000077 A EA 201000077A EA 201000077 A EA201000077 A EA 201000077A EA 201000077 A1 EA201000077 A1 EA 201000077A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
replication
heterological
disturbed
expression
Prior art date
Application number
EA201000077A
Other languages
English (en)
Other versions
EA018174B1 (ru
Inventor
Маркус Волшек
Андрей Егоров
Михаэль Бергманн
Томас Мустер
Христиан Киттель
Original Assignee
Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг filed Critical Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Publication of EA201000077A1 publication Critical patent/EA201000077A1/ru
Publication of EA018174B1 publication Critical patent/EA018174B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение охватывает новый вирус гриппа с нарушенной репликацией, включающий модифицированный NS1 сегмент, кодирующий NS1 белок, утративший функциональный домен связывания РНК и функциональный эффекторный домен, и гетерологичную последовательность, вставленную между донорным участком сплайсинга и акцепторным участком сплайсинга NS сегмента гена. Дополнительно изобретение охватывает применение вируса в качестве вектора для экспрессии различных белков, таких как хемокины, цитокины или антигенные структуры, способы получения вирусных частиц с применением указанного вирусного вектора, а также его применение для производства вакцин. Изобретение также охватывает составной белок, включающий часть N-конца NS1 белка и сигнальную последовательность, присоединенную к С-концу указанного NS1 белка.
EA201000077A 2007-06-27 2008-06-26 Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей EA018174B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94664407P 2007-06-27 2007-06-27
EP07450176A EP2048237A1 (en) 2007-10-05 2007-10-05 Replication deficient Influenza virus for the expression of heterologous sequences
PCT/EP2008/058154 WO2009007244A2 (en) 2007-06-27 2008-06-26 Replication deficient influenza virus for the expression of heterologous sequences

Publications (2)

Publication Number Publication Date
EA201000077A1 true EA201000077A1 (ru) 2010-06-30
EA018174B1 EA018174B1 (ru) 2013-06-28

Family

ID=39034019

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000077A EA018174B1 (ru) 2007-06-27 2008-06-26 Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей

Country Status (8)

Country Link
US (2) US20100136052A1 (ru)
EP (2) EP2048237A1 (ru)
CN (1) CN101796190A (ru)
AU (1) AU2008274360A1 (ru)
CA (1) CA2690317A1 (ru)
EA (1) EA018174B1 (ru)
NZ (1) NZ582099A (ru)
WO (1) WO2009007244A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072058A1 (en) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
EP2233152A1 (en) * 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
ES2557315T3 (es) * 2009-07-22 2016-01-25 Baxalta GmbH Nuevo virus de la gripe
US9217157B2 (en) * 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CN102821790A (zh) * 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
CA2801268A1 (en) * 2010-06-02 2011-12-08 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015063085A1 (en) 2013-10-28 2015-05-07 Thomas Muster Novel influenza virus vector for virotherapy
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
AU2018449744A1 (en) * 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US20220348958A1 (en) * 2019-07-23 2022-11-03 Oxford Biomedica (Uk) Limited Enhancing Production of Lentiviral Vectors
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021242597A1 (en) * 2020-05-23 2021-12-02 Wisconsin Alumni Research Foundation ("Warf") Ace2 expressing influenza virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
DK1086207T3 (da) * 1998-06-12 2007-05-29 Sinai School Medicine Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
RU2280690C2 (ru) * 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Рекомбинантные вирусы гриппа а
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US8137676B2 (en) * 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
AT502275B8 (de) * 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen

Also Published As

Publication number Publication date
WO2009007244A2 (en) 2009-01-15
EP2171070A2 (en) 2010-04-07
CN101796190A (zh) 2010-08-04
CA2690317A1 (en) 2009-01-15
US9187732B2 (en) 2015-11-17
US20140045245A1 (en) 2014-02-13
EP2048237A1 (en) 2009-04-15
WO2009007244A3 (en) 2009-05-07
EA018174B1 (ru) 2013-06-28
NZ582099A (en) 2012-06-29
AU2008274360A1 (en) 2009-01-15
US20100136052A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
EA201000077A1 (ru) Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
EA200801501A1 (ru) Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
DOP2013000080A (es) Antígeno gb de citomegalovirus
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
DK2344540T3 (da) Cd86-antagonist multimål bindingsproteiner
WO2015200357A3 (en) Nucleic acids for treatment of peanut allergies
AR077757A1 (es) Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
UY31504A1 (es) Construcciones de union de antigenos
ES2782119T3 (es) Antígenos de F de prefusión del VRS
EA201491049A1 (ru) Противораковый слитый белок
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2018093932A3 (en) Nucleic acids for treatment of allergies
WO2011034622A3 (en) Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
DK2059525T3 (da) Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse
WO2013001285A3 (en) Fmdv vp1 peptides
MX2013007146A (es) Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
WO2015019253A3 (en) Anti-dengue virus genetic vaccine based on the envelope protein ectodomains
WO2023109979A3 (zh) 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
CY1118060T1 (el) Εμβολιο δεικτης για κλασικη πανωλη των χοιρων

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU